Exchange

SAI.TECH Reports Fiscal Year 2023 Annual Report on Form 20-F

Retrieved on: 
Tuesday, April 23, 2024
The Annual Report, Annual, Annual report, Bank statement, Security (finance), Exchange

SINGAPORE, April 23, 2024 (GLOBE NEWSWIRE) -- SAI.TECH Global Corporation (“SAI.TECH” or “SAI” or the “Company”) (NASDAQ: SAI, SAITW), a sustainable distributed bitcoin mining operator and a clean-tech company that integrates the bitcoin mining, power, and heating industries, today reported its audited financial results for the fiscal year ended December 31, 2023, and filed with the Securities and Exchange Commission its Annual Report on Form 20-F for the fiscal year ended December 31, 2023.

Key Points: 
  • SINGAPORE, April 23, 2024 (GLOBE NEWSWIRE) -- SAI.TECH Global Corporation (“SAI.TECH” or “SAI” or the “Company”) (NASDAQ: SAI, SAITW), a sustainable distributed bitcoin mining operator and a clean-tech company that integrates the bitcoin mining, power, and heating industries, today reported its audited financial results for the fiscal year ended December 31, 2023, and filed with the Securities and Exchange Commission its Annual Report on Form 20-F for the fiscal year ended December 31, 2023.
  • The Annual Report is available on the Company’s investor relations website at https://ir.sai.tech.
  • The Company will provide a hard copy of the Annual Report containing the audited consolidated financial statements of the Company, free of charge, to a shareholder of the Company’s Class A ordinary shares upon written request.

SHCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sharecare Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Monday, April 22, 2024
CFO, News, Health, Annual report, Complaint, Communication, Exchange, Patient, Court, Person

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sharecare Inc. (“Sharecare” or “the Company”) (NASDAQ: SHCR) and certain of its officers.

Key Points: 
  • NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sharecare Inc. (“Sharecare” or “the Company”) (NASDAQ: SHCR) and certain of its officers.
  • According to the Complaint, Sharecare filed with the SEC its 2023 quarterly Form 10-Q reports on May 10, August 9, and November 9.
  • If you suffered a loss in Sharecare you have until June 18, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Retrieved on: 
Monday, April 22, 2024
Annual report, Exchange, File, CDMO, Form 10-K, Failure, Bank statement, Section

Jeff Wolf, CEO of Scorpius, stated, “We regret the delay in filing our Form 10-K, due in part to substantive changes within our organization.

Key Points: 
  • Jeff Wolf, CEO of Scorpius, stated, “We regret the delay in filing our Form 10-K, due in part to substantive changes within our organization.
  • Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the Exchange to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be.
  • During the six-month period from the date of the Filing Delinquency (the "Initial Cure Period"), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured.
  • Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond.

Qurax Exchange Unveils Multi-Chain Crypto Trading Platform with Integrated Financial Services and Revolutionary Crypto Card Program

Retrieved on: 
Monday, April 22, 2024
Crypto, KYC, Security, Mining, Investment, Exchange, AML, Cryptocurrency

The Qurax platform's multi-chain functionality supports seamless transactions across various blockchain networks, fostering unparalleled flexibility and accessibility in the crypto trading space.

Key Points: 
  • The Qurax platform's multi-chain functionality supports seamless transactions across various blockchain networks, fostering unparalleled flexibility and accessibility in the crypto trading space.
  • Full Stack Financial Services: From fiat onramps and offramps to advanced trading options, Qurax offers a comprehensive array of financial services, making it the go-to platform for all crypto-related activities.
  • Qurax Crypto Card: In a major stride towards cryptocurrency adoption, the Qurax Crypto Card will allow users to spend crypto assets directly from their exchange balance at millions of merchants globally.
  • The launch of Qurax exchange is not just the unveiling of another crypto exchange; it's the beginning of a new era in the digital finance world,", CEO of Qurax Exchange.

Vision Sensing Acquisition Corp. Receives Positive Ruling from Nasdaq Hearings Panel

Retrieved on: 
Friday, April 19, 2024
Language, Hearing, Security (finance), Form 10-Q, Exchange, VSAC, Letter, Form, Panel, Acquisition, Venture round, Series, File, Cryptocurrency

On January 23, 2024, the Company submitted an appeal to the appeal Staff’s determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

Key Points: 
  • On January 23, 2024, the Company submitted an appeal to the appeal Staff’s determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.
  • This submission included a detailed Compliance Plan, to present to the Panel, to regain compliance with the Listing Rules and also requested a stay of the suspension of the Company’s securities.
  • On January 24, 2024, the Company was notified, by the Nasdaq Hearings Advisor, that the hearing is scheduled to be held on April 4, 2024.
  • The Company intends to vigorously pursue its plan to return to compliance with the Nasdaq listing criteria on or prior to July 15, 2024.

EVe Mobility Acquisition Corp Receives NYSE Notice Regarding Late Filing of Annual Report on Form 10-K

Retrieved on: 
Friday, April 19, 2024
Delinquent, Annual report, Security (finance), Exchange, File, Acquisition, Bank statement, Medical device

Reference is made to the Company’s Notification of Late Filing on Form 12b-25 (filed with the SEC on March 27, 2024) as amended through the filing of a Form 12b-25/A with the SEC on April 15, 2024, which describe the circumstances leading to the late filing of the Delinquent Report.

Key Points: 
  • Reference is made to the Company’s Notification of Late Filing on Form 12b-25 (filed with the SEC on March 27, 2024) as amended through the filing of a Form 12b-25/A with the SEC on April 15, 2024, which describe the circumstances leading to the late filing of the Delinquent Report.
  • Additional time is needed by the Company to complete its review of the financial statements included in the Delinquent Report to ensure a complete, accurate Delinquent Report.
  • The Company intends to file the Delinquent Report as soon as practicable and in any event within the six-month period.
  • If the Company fails to file the Delinquent Report during the Initial Cure Period, the Exchange may, in its sole discretion, grant an up to six-month additional cure period (the "Additional Cure Period").

Cumulus Media Announces Amendment and Extension of Withdrawal Deadline and Expiration Time for Exchange Offer and Consent Solicitation

Retrieved on: 
Friday, April 19, 2024
Exchange offer, Settlement date, Issuer, Exchange, Solicitation, Credit, Letter, Note, Security (finance)

The Exchange Offer and Consent Solicitation will expire at the Amended Expiration Time, unless extended or terminated.

Key Points: 
  • The Exchange Offer and Consent Solicitation will expire at the Amended Expiration Time, unless extended or terminated.
  • In addition, neither this announcement nor the Exchange Offer is an offer to participate in the Term Loan Exchange Offer.
  • The Exchange Offer is conditioned upon the consummation of the Term Loan Exchange Offer and there can be no assurances that the Term Loan Exchange Offer will be consummated on the terms described in the Offering Memorandum or at all.
  • The Term Loan Exchange Offer is also conditioned upon the consummation of the Exchange Offer.

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

Retrieved on: 
Thursday, April 18, 2024
Sale, Regulation D, Form S-1, NOS, Security (finance), Hypoplastic left heart syndrome, Exchange, Public expenditure, Form, Exercise, HLHS, Clinical trial

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The new warrants are immediately exercisable at an exercise price of $2.35 per share.
  • The gross proceeds to the Company from the warrant exercise offering were approximately $6.2 million, prior to deducting placement agent fees and offering expenses payable by the Company.
  • The total gross proceeds to the Company from the two offerings, this warrant exercise offering and the previously announced public offering, with gross proceeds of approximately $5.2 million, which closed on April 10, 2024, in each case, prior to deducting placement agent fees and offering expenses payable by the Company, were approximately $11.4 million.

Cumulus Media Announces Further Additional Extension of Expiration Time in Exchange Offer and Consent Solicitation Relating to 6.750% Senior Secured First-Lien Notes due 2026

Retrieved on: 
Thursday, April 18, 2024
Exchange offer, Settlement date, CMLS, Consent, Exchange, Solicitation, Senior, Letter, Note, Security (finance)

The Exchange Offer and Consent Solicitation will expire at the Newly Extended Expiration Time, unless extended or terminated.

Key Points: 
  • The Exchange Offer and Consent Solicitation will expire at the Newly Extended Expiration Time, unless extended or terminated.
  • Questions or requests for assistance related to the Exchange Offer and Consent Solicitation or for additional copies of the Exchange Offer Documents may be directed to D.F.
  • You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Exchange Offer and Consent Solicitation.
  • The Exchange Offer and Consent Solicitation is being made solely by the Offering Memorandum.

Cumulus Media Announces Further Additional Extension of Expiration Time in Exchange Offer and Consent Solicitation Relating to 6.750% Senior Secured First-Lien Notes due 2026

Retrieved on: 
Wednesday, April 17, 2024
Exchange offer, Settlement date, CMLS, Consent, Exchange, Solicitation, Senior, Letter, Note, Security (finance)

The Exchange Offer and Consent Solicitation will expire at the New Additionally Extended Expiration Time, unless extended or terminated.

Key Points: 
  • The Exchange Offer and Consent Solicitation will expire at the New Additionally Extended Expiration Time, unless extended or terminated.
  • Questions or requests for assistance related to the Exchange Offer and Consent Solicitation or for additional copies of the Exchange Offer Documents may be directed to D.F.
  • You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Exchange Offer and Consent Solicitation.
  • The Exchange Offer and Consent Solicitation is being made solely by the Offering Memorandum.